BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 314 filers reported holding BLUEBIRD BIO INC in Q2 2018. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $44,000 | -39.7% | 2,290 | 0.0% | 0.00% | -40.0% |
| Q2 2021 | $73,000 | -18.0% | 2,290 | -22.2% | 0.01% | -16.7% |
| Q1 2021 | $89,000 | +85.4% | 2,945 | +166.8% | 0.01% | +50.0% |
| Q4 2020 | $48,000 | +11.6% | 1,104 | +38.0% | 0.00% | 0.0% |
| Q3 2020 | $43,000 | -12.2% | 800 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $49,000 | +32.4% | 800 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $37,000 | -47.1% | 800 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $70,000 | -4.1% | 800 | 0.0% | 0.01% | -14.3% |
| Q3 2019 | $73,000 | -28.4% | 800 | 0.0% | 0.01% | -36.4% |
| Q2 2019 | $102,000 | -19.0% | 800 | 0.0% | 0.01% | -26.7% |
| Q1 2019 | $126,000 | +59.5% | 800 | 0.0% | 0.02% | +36.4% |
| Q4 2018 | $79,000 | -32.5% | 800 | 0.0% | 0.01% | -26.7% |
| Q3 2018 | $117,000 | -7.1% | 800 | 0.0% | 0.02% | -11.8% |
| Q2 2018 | $126,000 | -8.0% | 800 | 0.0% | 0.02% | -10.5% |
| Q1 2018 | $137,000 | -3.5% | 800 | 0.0% | 0.02% | -13.6% |
| Q4 2017 | $142,000 | – | 800 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
| qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
| Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
| Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
| Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
| HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
| Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
| PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
| Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
| Summit X, LLC | 103,424 | $651,000 | 0.19% |